Physician profile
Boris Leybel
NPI 1578508685
$58,251.64
in general payments reported to CMS, 2019-2025
45 companies · $4,660 in 2025
The $4,660 reported for 2025 was more than what 86% of Pain Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $3,122 · 2021: $21K · 2022: $15K · 2023: $6,664 · 2024: $6,373 · 2025: $4,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $7,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,149.80 |
| Food and Beverage | $7,547.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21,956.38 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $12,645.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $7,620.22 | 2022 | |
| Allergan, INC. | $2,758.55 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $2,235.86 | 2020-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Scilex Pharmaceuticals INC. | $1,660.30 | 2021-2025 | Ztlido |
| Mdd US Operations, LLC | $1,131.99 | 2019-2025 | Apokyn, Xadago, Apokyn |
| Pfizer INC. | $1,099.73 | 2019-2025 | |
| Horizon Therapeutics Plc | $860.47 | 2019-2022 | |
| Lilly USA, LLC | $700.72 | 2019-2024 | Emgality, Reyvow |
| Neurocrine Biosciences, INC. | $517.94 | 2020-2025 | Ingrezza, Ongentys |
| Upsher-Smith Laboratories LLC | $487.16 | 2020-2023 | |
| Collegium Pharmaceutical, INC. | $382.21 | 2019-2025 | Xtampza |
| Amgen INC. | $336.78 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $333.09 | 2021-2025 | Rytary, Crexont, Brekiya |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Leybel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.